Recent Updates
Recently added Catalysts
PLRX

Pliant Therapeutics to Participate in BTIG Biotechnology Conference

Key Takeaway: SOUTH SAN FRANCISCO, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D.

Full Press Release Details

SOUTH SAN FRANCISCO, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer, will participate in a panel discussion at the BTIG Biotechnology Conference 2022.
Panel: Drug Development in Pulmonary Medicine: Emerging Trends and a Review of the Unmet Need
Date: Tuesday, August 9, 2022
Time: 1:00 p.m. ET | 10:00 a.m. PT
The live and replay sessions of the panel discussion will be available to conference registrants via the BTIG Biotechnology Conference 2022 portal.
About Pliant Therapeutics, Inc.
Investor and Media Contact:
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
Last updated: Aug 2, 2022